Reader Comments

Post a new comment on this article

Why this paper helps...

Posted by CHKing on 08 Dec 2007 at 21:46 GMT

Because lymphatic filariasis (LF) elimination efforts are hampered by a dearth of economic information about the cost of mass drug administration (MDA) programs (using either albendazole with diethylcarbamazine [DEC] or albendazole with ivermectin), a multicenter study was undertaken to determine the costs of MDA programs to interrupt transmission of infection with LF. Such results are particularly important because LF programs have the necessary diagnostic and treatment tools to eliminate the disease as a public health problem globally, and already by 2006, the Global Programme to Eliminate LF had initiated treatment programs covering over 400 million of the 1.3 billion people at risk.Methodol

The advance provided by this paper is the parallel analysis of costs data on the efforts for Lymphatic Filariasis elimination. Accurate cost-effectiveness analysis requires inputs such as these, across a range of locations and a range of program structures. Those who are concerned about the continued participation of Community Health volunteers will be able to examine available results from various settings.
Charles King
Academic Editor